Dr. Wang on Combatting CAR T-Cell Therapy Resistance in MCL

Video

Michael Wang, MD, discusses resistance to CAR T-cell therapy and the next steps to overcoming this challenge in treatment for mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses resistance to CAR T-cell therapy and the next steps to overcoming this challenge in treatment for mantle cell lymphoma (MCL).

CD19-targeted CAR T-cell therapy can put some patients with MCL into long-term remission, but most will relapse, according to Wang. Therefore, there need to be ways to overcome CAR T-cell resistance, which might be due to the loss of an antigen or because the parallel pathways are overly activated, explains Wang. If CD19 is lost, new targets need to be found. One method, Wang says, is attacking 2 targets at the same time to overcome some of the resistance by loss of 1 target. Currently, MCL treatment does not commercially include CAR T cells.

In an era of precision medicine, DNA/RNA epigenetic mutations could be used to wield the discrete mechanism of resistance in each patient and then target this pathway to overcome resistance in a personalized fashion, concludes Wang.

Recent Videos
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Related Content
© 2025 MJH Life Sciences

All rights reserved.